Medicine:Kostmann syndrome

From HandWiki
Kostmann syndrome

Kostmann syndrome is a group of diseases that affect myelopoiesis, causing a congenital form of neutropenia (severe congenital neutropenia [SCN]), usually without other physical malformations. SCN manifests in infancy with life-threatening bacterial infections.[1]

Most cases of SCN respond to treatment with granulocyte colony-stimulating factor (filgrastim), which increases the neutrophil count and decreases the severity and frequency of infections.[1] Although this treatment has significantly improved survival, people with SCN are at risk of long-term complications such as hematopoietic clonal disorders (myelodysplastic syndrome, acute myeloid leukemia).

Kostmann disease (SCN3), the initial subtype recognized, was clinically described in 1956. This type has an autosomal recessive inheritance pattern, whereas the most common subtype of Kostmann syndrome, SCN1, shows autosomal dominant inheritance.

Presentation

Infants with SCN have frequent infections: 50% have a significant infection within 1 month, most others by 6 months.[2] Their etiology is usually bacterial, especially staphylococcal, and they commonly involve abscesses, both cutaneous and of internal organs, pneumonia, mastoiditis (inflammation of the mastoid process), and sepsis. All of these are life-threatening for infants.[3]

Genetics

Subtypes of SCN
OMIM Name Gene Chromosome Gene/Locus MIM number
202700 SCN1 ELANE 19p13.3 130130[4]
613107 SCN2 GFI1 1p22.1
610738 SCN3 HAX1 1q21.3
612541 SCN4 G6PC3 17q21.31
615285 SCN5 VPS45 1q21.2
300299 SCNX WASP Xp11.23 300392[5]
Kostmann disease, which is SCN3, is inherited in an autosomal recessive pattern.
The most common form of Kostmann syndrome, SCN1, is autosomal dominant.

Kostmann disease, SCN3, is inherited in an autosomal recessive manner, but the commonest subtype of Kostmann syndrome, SCN1, is autosomal dominant.[6]

A significant proportion of SCN lacks a known mutation.[7] The recognized subtypes of Kostmann syndrome are:

  • SCN1 is the commonest form of SCN, which accounts for 60-80% of SCN,[2] and the first to be genetically typified.[2] This autosomal dominant form that arises from mutations of the ELANE (formerly ELA2) gene on chromosome 19p13.3, which encodes neutrophil elastase.[4] Over a hundred ELANE mutations have been found in SCN1.[8] This same gene is mutated in cyclic neutropenia.[8]
  • SCN2 is caused by heterozygous (autosomal dominant) mutation of the GFI1 gene on chromosome 1p22.[9] GFI1 is a repressor of several transcriptional processes, including ELANE,[2][9] as well as miR-21 and miR-196b micro-RNAs which influence myelopoiesis.[2]
  • SCN3 is the "classical", autosomal recessive form of Kostmann disease which arises from homozygous mutations in the HAX1 gene on chromosome 1p22.1. About one third of SCN3 individuals also have neurological changes including seizures, learning disabilities, or developmental delay.[2]
  • SCN4 is caused by autosomal recessive mutation of the G6PC3 gene on 17q21.[10] SCN4 is associated with structural cardiac abnormalities, enlarged liver, intermittent thrombocytopenia and a prominent superficial venous pattern.[10] A subset of SCN4 has severe primary pulmonary hypertension and respiratory failure.[10]
  • SCN5 arises from autosomal recessive Thr224Asn mutation in the VPS45 gene on chromosome 1q21.2.[11] Unlike classical Kostmann disease, SCN5 also has defective platelet aggregation (thrombasthenia) and myelofibrosis.[12] This type is refractory to granulocyte colony-stimulating factor. There is an absence of lysosomes in fibroblasts and depletion of alpha granules in platelets. Accelerated apoptosis occurs in the neutrophils and bone marrow.
  • X-linked SCN (SCNX) is caused by mutation in the WASP gene on Xp11.[13]

SCN occasionally may arise from SBDS mutations.[7]

Usage

Kostmann disease is a form of severe congenital neutropenia (SCN), specifically type 3 (SCN3),[14] which is a rare autosomal recessive condition in which severe chronic neutropenia is detected soon after birth.[6][15] The disorder was discovered in 1956 in an extended family in northern Sweden by Rolf Kostmann, a Swedish doctor.[16][17]

Severe congenital neutropenia (SCN) is used as the overarching term for all diseases that affect myelopoiesis most prominently. Kostmann syndrome can restrictively refer to Kostmann disease specifically, or can be used synonymously with SCN as an umbrella term. These syndrome subtypes are phenotypically similar despite arising from different gene abnormalities.[2]

Although mutations of more than 15 genes cause severe congenital neutropenia (in a general sense)[18] not all of these are usually considered as SCN. Clinical usage excludes two broad categories of congenital neutropenia. Diseases are excluded that overtly affect multiple systems rather than impacting myelopoiesis most prominently. Thus SCN excludes the severe neutropenia which can occur in congenital diseases such as Shwachman–Diamond syndrome, Barth syndrome, Chédiak–Higashi syndrome, WHIM syndrome, and glycogen storage disease type Ib.[18] A further group of other miscellaneous inherited disorders, such as hyper IgM syndrome, Hermansky–Pudlak syndrome (HPS), Griscelli syndrome (GS), PN, P14 deficiency, Cohen syndrome, Charcot–Marie–Tooth disease (CMT) can show congenital neutropenia, but lack bone marrow findings typical of SCN.

This group of diseases may also have additional features such as partial albinism, retinopathy, or neuropathy, and are not inclined to degenerate into acute myelogenous leukemia.[2]

GATA2 deficiency

GATA2 deficiency is a grouping of several disorders caused by common defect, viz., familial or sporadic inactivating mutations in one of the two parental GATA2 genes. These autosomal dominant mutations cause a reduction, i.e. a haploinsufficiency, in the cellular levels of the gene's product, GATA2. The GATA2 protein is a transcription factor critical for the embryonic development, maintenance, and functionality of blood-forming, lympathic-forming, and other tissue-forming stem cells. In consequence of these mutations, cellular levels of GATA2 are deficient and individuals develop over time hematological, immunological, lymphatic, or other presentations that may begin as apparently benign abnormalities but commonly progress to a more serious disorder. A small but significant percentage of individuals with GATA2 deficiency's present with congenital neutropenia. This neutropenia is typically mild, often persists for years, and therefore is not a Kostmann syndrome disorder. Over time, however, the deficiency commonly progresses to include thrombocytopenia, increases susceptibility to infections due to, e.g. atypical mycobacteria or human papillomavirus, dysfunction of non-hematological organs, the myelodysplastic syndrome, and/or a leukemia, particularly acute myelogenous leukemia.[19][20][21]

Pathophysiology

The various mutations may be responsible for the untimely initiation of apoptosis in myelocytes, producing their premature destruction. There may be, in addition, other underlying molecular/genetic changes producing DNA mutations and genome instability, which contribute to initiation and progression of this disease.

Diagnosis

An absolute neutrophil count (ANC) chronically less than 500/mm3, usually less than 200/mm3, is the main sign of Kostmann's. Other elements include the severity of neutropenia, the chronology (from birth; not emerging later), and other normal findings (hemoglobin, platelets, general body health). Isolated neutropenia in infants can occur in viral infections, autoimmune neutropenia of infancy, bone marrow suppression from a drug or toxin, hypersplenism, and passive placental transfer of maternal IgG.[2]

A bone marrow test can assist in diagnosis. The bone marrow usually shows early granulocyte precursors, but myelopoietic development stops ("arrests") at the promyelocyte and/or myelocyte stage, so that few maturing forms are seen. Neutrophil survival is normal.

Needs mention of (rarer) myelokathexis types. e.g. G6PC3 variant and

Therapy

Regular administration of exogenous granulocyte colony-stimulating factor (filgrastim) clinically improves neutrophil counts and immune function and is the mainstay of therapy, although this may increase risk for myelofibrosis and acute myeloid leukemia in the long term.[22]

Over 90% of SCN responds to treatment with granulocyte colony-stimulating factor (filgrastim), which has significantly improved survival.

See also

References

  1. ↑ 1.0 1.1 Boztug, K; Appaswamy, G; Ashikov, A; Schäffer, AA; Salzer, U; Diestelhorst, J; Germeshausen, M; Brandes, G et al. (1 January 2009). "A syndrome with congenital neutropenia and mutations in G6PC3.". The New England Journal of Medicine 360 (1): 32–43. doi:10.1056/nejmoa0805051. PMID 19118303. 
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 Hoffman, R; Benz, EJ; Silberstein, LE; Heslop, H; Weitz J; Anastasi, J. (2012). Hematology: Basic Principles and Practice (6th ed.). Elsevier. ISBN 978-1-4377-2928-3. 
  3. ↑ Kawalec, Wanda (2015). Pediatria. Warsaw: PZWL. pp. 1070. ISBN 978-83-200-4631-1. 
  4. ↑ 4.0 4.1 Elastase, neutrophil-expressed; ELANE. Online Mendelian Inheritance in Man. Johns Hopkins University. [1]
  5. ↑ WAS gene; WAS. Online Mendelian Inheritance in Man. Johns Hopkins University. [2]
  6. ↑ 6.0 6.1 "Kostmann syndrome and severe congenital neutropenia". Semin. Hematol. 39 (2): 82–8. 2002. doi:10.1053/shem.2002.31913. PMID 11957189. http://linkinghub.elsevier.com/retrieve/pii/S0037196302500172. 
  7. ↑ 7.0 7.1 Xia J, Bolyard AA, Rodger E et al. Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropenia. Br J Haematol. 2009;147(4):535. PMID|19775295
  8. ↑ 8.0 8.1 Germeshausen, M., Deerberg, S., Peter, Y., et al. The spectrum of ELANE mutations and their implications in severe congenital and cyclic neutropenia. Hum. Mutat. 34: 905-914, 2013. PMID|23463630]
  9. ↑ 9.0 9.1 Neutropenia, Severe Congenital, 2, Autosomal Dominant; SCN2. Online Mendelian Inheritance in Man. Johns Hopkins University. [3]
  10. ↑ 10.0 10.1 10.2 Neutropenia, Severe Congenital, 4, Autosomal Recessive; SCN4. Online Mendelian Inheritance in Man. Johns Hopkins University. [4]
  11. ↑ Neutropenia, Severe Congenital, 5, Autosomal Recessive; SCN5. Online Mendelian Inheritance in Man. Johns Hopkins University. [5]
  12. ↑ "The Thr224Asn mutation in the VPS45 gene is associated with the congenital neutropenia and primary myelofibrosis of infancy". Blood 121 (25): 5078–87. June 2013. doi:10.1182/blood-2012-12-475566. PMID 23599270. http://bloodjournal.hematologylibrary.org/cgi/pmidlookup?view=long&pmid=23599270. 
  13. ↑ Neutropenia, Severe Congenital, X-linked; SCNX. Online Mendelian Inheritance in Man. Johns Hopkins University. [6]
  14. ↑ Online Mendelian Inheritance in Man (OMIM) Neutropenia, Severe congenital, 3, Autosomal recessive; SCN3 -610738
  15. ↑ "Congenital neutropenia". Clin Perinatol 31 (1): 29–38. 2004. doi:10.1016/j.clp.2004.03.011. PMID 15183654. http://linkinghub.elsevier.com/retrieve/pii/S0095510804000120. 
  16. ↑ Kostmann R (1956). "Infantile genetic agranulocytosis; agranulocytosis infantilis hereditaria.". Acta Paediatr 45 (Suppl 105): 1–78. doi:10.1111/j.1651-2227.1956.tb06875.x. PMID 13326376. 
  17. ↑ Klein, C.; Grudzien, M.; Appaswamy, G.; Germeshausen, M.; Sandrock, I.; Schäffer, A. A.; Rathinam, C.; Boztug, K. et al. (Jan 2006). "HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease)". Nature Genetics 39 (1): 86–92. doi:10.1038/ng1940. PMID 17187068. 
  18. ↑ 18.0 18.1 McDermott DH, De Ravin SS, Jun HS et al. Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis. Blood. 2010;116(15):2793. PMID|20616219
  19. ↑ "Spectrum of myeloid neoplasms and immune deficiency associated with germline GATA2 mutations". Cancer Medicine 4 (4): 490–9. April 2015. doi:10.1002/cam4.384. PMID 25619630. 
  20. ↑ "GATA factor mutations in hematologic disease". Blood 129 (15): 2103–2110. April 2017. doi:10.1182/blood-2016-09-687889. PMID 28179280. 
  21. ↑ "Heterogeneity of GATA2-related myeloid neoplasms". International Journal of Hematology 106 (2): 175–182. August 2017. doi:10.1007/s12185-017-2285-2. PMID 28643018. 
  22. ↑ Essential Haematology. Blackwell Publishing. 2005. ISBN 978-1-4051-3649-5. 

Further reading

External links

Classification
External resources




Retrieved from "https://handwiki.org/wiki/index.php?title=Medicine:Kostmann_syndrome&oldid=2865025"